Last viewed: KMPH


Prices are updated after-hours



nasdaq:KMPH KemPharm Inc

KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing

(0.0% 1d) (-2.4% 1m) (-64.7% 1y) (0.0% 2d) (-3.4% 3d) (-2.4% 7d) (-38.72% volume)
Earnings Calendar:
http://www.kempharm.com/
Sec Filling | Patents | 22 employees

(US) KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

urea   treatment   profitable  

add to watch list email alert is off

Price chart


% (High / Open) change chart




Press-releases


Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Published: 2022-06-08 (Crawled : 22:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing
| | O: -0.61% H: 2.06% C: -0.21%

report results publication
Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Published: 2022-06-07 (Crawled : 22:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing
| | O: -0.99% H: 2.4% C: -2.0%

report results publication
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
Published: 2022-05-31 (Crawled : 17:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing
| | O: 0.64% H: 1.69% C: -1.91%


Updated Financial Calendar for 2022
Published: 2022-05-16 (Crawled : 13:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing
| | O: -3.04% H: 10.84% C: 5.78%

for
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
Published: 2022-05-16 (Crawled : 01:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing
| | O: -3.04% H: 10.84% C: 5.78%

acquisition rare disease
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
Published: 2022-05-15 (Crawled : 00:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing
| | O: -3.04% H: 10.84% C: 5.78%


KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)
Published: 2022-03-16 (Crawled : 12:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing
| | O: 1.37% H: 3.47% C: 1.93%

adlarity fda fda approval derm approval system one transdermal system
Central Nervous System (CNS) Stimulant Drugs Market to grow at a CAGR of 5.74 by 2026 | Rise in CNS Disorders to Boost Growth | 17000+ Technavio Reports
Published: 2022-03-14 (Crawled : 16:00) - prnewswire.com
GSK | News | $43.35 -0.8% -0.16% | twitter stocktwits trandingview |
Health Technology
| | O: 0.42% H: 0.0% C: 0.0%
NVS | News | $84.17 -1.3% 0.12% | twitter stocktwits trandingview |
Health Technology
| | O: 0.54% H: 0.0% C: 0.0%
ENDP | $0.71 85.33% 2.54% | twitter stocktwits trandingview |
Health Technology
| | O: -1.72% H: 3.51% C: -5.26%
GLAXF | News | $21.99 4.22% | twitter stocktwits trandingview |
Health Technology
| | O: 9.61% H: 0.0% C: -0.57%
BIIB | $202.51 -5.18% 1.43% | twitter stocktwits trandingview |
Health Technology
| | O: 0.47% H: 1.48% C: -2.43%
NVSEF | News | $84.85 1.0% | twitter stocktwits trandingview |
Health Technology
| | O: -3.28% H: 0.0% C: 0.0%
KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing
| | O: 0.0% H: 1.34% C: -4.4%
TMO | News | $535.77 -1.45% -1.84% | twitter stocktwits trandingview |
Health Technology
| | O: -1.31% H: 0.0% C: 0.0%
JAZZ | News | $155.24 -0.93% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.1% H: 1.14% C: -0.59%
ALPMF | News | $16.71 5.56% | twitter stocktwits trandingview |
Health Technology
| | O: 0.7% H: 0.0% C: 0.0%
SNYNF | News | $108.84 4.15% | twitter stocktwits trandingview |
Health Technology
| | O: -2.53% H: 0.0% C: -0.08%
ALPMY | News | $16.14 1.19% | twitter stocktwits trandingview |
Manufacturing
| | O: 2.42% H: 0.31% C: -0.47%
VTRS | News | $10.9 -1.54% 1.19% | twitter stocktwits trandingview |
Health Technology
| | O: 1.4% H: 1.08% C: -3.44%
SNY | News | $52.14 -0.88% -0.38% | twitter stocktwits trandingview |
Health Technology
| | O: -3.24% H: 0.0% C: 0.0%

order drug system nervous system report growth
KemPharm to Report Fourth Quarter and Full-Year 2021 Results
Published: 2022-03-10 (Crawled : 12:30) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing
| | O: 0.18% H: 0.99% C: -2.52%

report results
KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | twitter stocktwits trandingview |
Manufacturing
| | O: -9.75% H: 3.23% C: -0.91%

trial results topline
See all


Last 15 days Sec forms
File Id Form Published Date Transaction Date Direction Code Amount Transacted Owned Amount
0001437749-22-013706 4 2022-05-27 2022-05-25 Buy P 2000 5835
0001437749-22-013570 4 2022-05-26 2022-05-25 Buy P 10000 11034
0001437749-22-013570 4 2022-05-26 2022-05-25 Buy P 1000 39521
0001437749-22-013570 4 2022-05-26 2022-05-25 Buy P 2000 38521
0001437749-22-013468 4 2022-05-25 2022-05-20 Buy P 200 200


Your Today's Watch List
Sign in to create a watchlist
Last 48 Hours Insiders Buying
ALTG P 3227 | $9.29 -2.52% 0.0% | twitter stocktwits trandingview |
Distribution Services
| 01:40
SKIL P 30000 | $3.61 -6.96% 2.22% | twitter stocktwits trandingview |
Information
| 23:50
CAMP P 20000 | $4.65 -1.27% 0.86% | twitter stocktwits trandingview |
Electronic Technology
| 16:00